Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Egg Harbor Township, NJ
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Egg Harbor Township, NJ
Click here to add this to my saved trials
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Great Neck, NY
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Great Neck, NY
Click here to add this to my saved trials
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Charlotte, NC
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Wilmington, NC
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Germantown, TN
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Nashville, TN
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
San Antonio, TX
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Logan, UT
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Logan, UT
Click here to add this to my saved trials
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Ogden, UT
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Research Site
mi
from
Kurralta Park,
AMG 827 in Subjects With Moderate to Severe Crohn's Disease
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Research Site
mi
from
Kurralta Park,
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Providence Hospital,
mi
from
Mobile, AL
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Providence Hospital,
mi
from
Mobile, AL
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
NEA Baptist Memorial Hospital
mi
from
Jonesboro, AR
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
NEA Baptist Memorial Hospital
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Front Range Cancer Specialists
mi
from
Fort Collins, CO
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Front Range Cancer Specialists
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Poudre Valley Hospital
mi
from
Fort Collins, CO
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Poudre Valley Hospital
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Kapiolani Medical Center for Women and Children
mi
from
Honolulu, HI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Kuakini Medical Center
mi
from
Honolulu, HI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Kuakini Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
OnCare Hawaii-Liliha
mi
from
Honolulu, HI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
OnCare Hawaii-Liliha
mi
from
Honolulu, HI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Oncare Hawaii Inc-Kuakini
mi
from
Honolulu, HI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Oncare Hawaii Inc-Kuakini
mi
from
Honolulu, HI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Queen's Medical Center
mi
from
Honolulu, HI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Straub Clinic And Hospital
mi
from
Honolulu, HI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Straub Clinic And Hospital
mi
from
Honolulu, HI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Castle Medical Center
mi
from
Kailua, HI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Castle Medical Center
mi
from
Kailua, HI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Wilcox Memorial Hospital and Kauai Medical Clinic
mi
from
Lihue, HI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Wilcox Memorial Hospital and Kauai Medical Clinic
mi
from
Lihue, HI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Reid Hospital & Health Care Services
mi
from
Richmond, IN
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Reid Hospital & Health Care Services
mi
from
Richmond, IN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Saint Rose Ambulatory and Surgery Center
mi
from
Great Bend, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Saint Rose Ambulatory and Surgery Center
mi
from
Great Bend, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Hays Medical Center
mi
from
Hays, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Hays Medical Center
mi
from
Hays, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Kansas City Cancer Centers - Southwest
mi
from
Overland Park, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Kansas City Cancer Centers - Southwest
mi
from
Overland Park, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Via Christi Hospital-Pittsburg
mi
from
Pittsburg, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Via Christi Hospital-Pittsburg
mi
from
Pittsburg, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas, PA - Salina
mi
from
Salina, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Salina Regional Health Center.
mi
from
Salina, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Salina Regional Health Center.
mi
from
Salina, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Kansas City Cancer Center, Shawnee Mission
mi
from
Shawnee Mission, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Kansas City Cancer Center, Shawnee Mission
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Saint Francis Hospital and Medical Center - Topeka
mi
from
Topeka, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Saint Francis Hospital and Medical Center - Topeka
mi
from
Topeka, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas, PA - Wellington
mi
from
Wellington, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Associates in Women's Health
mi
from
Wichita, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Associates in Women's Health
mi
from
Wichita, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas-Wichita Medical Arts Tower
mi
from
Wichita, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas-Wichita Medical Arts Tower
mi
from
Wichita, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Wichita CCOP
mi
from
Wichita, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Wichita CCOP
mi
from
Wichita, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Via Christi Regional Medical Center
mi
from
Wichita, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Via Christi Regional Medical Center
mi
from
Wichita, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas, PA - Winfield
mi
from
Winfield, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials